News Channels

17 Jun 2017 Cerveau Technologies, Inc. Announces FDA Acceptance of Investigational New Drug (IND) for Tau Imaging Agent MK-6240
17 Jun 2017 Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
17 Jun 2017 ADC Therapeutics Presents First Clinical Data from its Novel Antibody-Drug Conjugate ADCT-402 at the International Conference on Malignant Lymphoma
15 Jun 2017 RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA™) for H. pylori Infection
15 Jun 2017 Inovio Fully Enrolls 160 Subjects in Puerto Rico for Second Zika Vaccine Phase 1 Trial; Continues Leadership to Advance an Effective Preventive Solution
15 Jun 2017 Debiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN
15 Jun 2017 Seattle Genetics and Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed Hodgkin Lymphoma at the International Conference on Malignant Lymphoma
15 Jun 2017 LEO Pharma Starts Phase 3 Clinical Study for Tralokinumab in Atopic Dermatitis
15 Jun 2017 Generon Announces the Initiation of a Phase I Clinical Study for A-337, a CD3-Activating Bi-Specific Antibody Targeting EpCAM to Treat Solid Tumors
15 Jun 2017 Novartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years
15 Jun 2017 Dose-escalation data show favorable safety profile and promising clinical activity for IPH4102
15 Jun 2017 BioTime’s Renevia® Achieves Primary Endpoint in European Pivotal Trial
15 Jun 2017 GenSight Biologics Reports Long-Term Positive Safety and Visual Acuity Results at Week 96 in Phase I/II Study of GS010 for the Treatment of Leber’s Hereditary Optic Neuropathy (LHON)
15 Jun 2017 Catalyst Biosciences and ISU Abxis Complete Dosing of First Patient Cohort in Hemophilia B Clinical Trial
14 Jun 2017 Aldeyra Therapeutics Announces Results from Allergic Conjunctivitis Phase 2b Clinical Trial and Plans for Phase 3 Clinical Testing
14 Jun 2017 Janssen Presents Long Term Phase 3 Efficacy and Safety Data of Sirukumab in Rheumatoid Arthritis Patients Who had an Inadequate Response and/or Who Were Intolerant to Anti-TNFs
14 Jun 2017 MabVax Therapeutics Reports Positive Phase 1 Results for MVT-2163 ImmunoPET Imaging Agent
14 Jun 2017 Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus
14 Jun 2017 Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®
14 Jun 2017 Celltrion Healthcare showcases data supporting the efficacy and safety of Truxima® (CT-P10, biosimilar rituximab) in advanced follicular lymphoma and rheumatoid arthritis

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing